Several bacteria have emerged as significant health threats in recent years;
antibiotics is expected to reach US$2 billion in 2006.
Immtech's proprietary chemical library has yielded a unique class of aromatic dications
with potent activity against a panel of methicillin-sensitive staph (Staphylococcus aureus,
MSSA), methicillin-resistant staph (MRSA) and vancomycin-resistant enterococcus (VRE), in
addition to a broad range of other gram positive aerobic and anaerobic bacteria. A second
round of testing of a more focused subclass of compounds further refined the structure-activity
relationships for this new class, and provided a launch point for advanced in vivo testing.